PR Newswire updates

10.5
2026
The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
10.5
2026
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
10.5
2026
ICAC and UNODC jointly debut the pioneering Prison Guide, ICAC Commissioner: charting the way for enhancing global prison integrity

ZHUOYU Showcases Advanced Vehicle Intelligence Solutions at Auto Shanghai 2025
April 25, 2025
CLOU Electronics honored as a TOP 5 Battery & Energy Storage Innovation Company at Battery Energy Storage Indonesia 2025
April 25, 2025
State Grid Xinjiang Information & Telecommunication Company: Facial Recognition Enhances Enterprise Security Management
April 25, 2025
SERES Debuts Intelligent Safety at Auto Shanghai 2025, Setting Industry Standard and Capturing Global Spotlight
April 25, 2025
Rizhao, Shandong's sunshine destination, prepares for influx of tourists
April 25, 2025
Neusoft Launches Three Product Portfolios for AI-Powered Intelligent Mobility at Auto Shanghai 2025
April 25, 2025
2 Billion USD Polypropylene (PP) Production Plant and Terminal Investment to Contribute $300 Million Annually to Türkiye's Trade Balance
April 25, 2025
Fosun Develops Business for Good and Creates IMPACT
April 25, 2025

The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth

The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth

Global anniversary campaign marks the first step of the brand’s transformation…

Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers

Published multicenter study found higher complete wound closure rates and faster…

ICAC and UNODC jointly debut the pioneering Prison Guide, ICAC Commissioner: charting the way for enhancing global prison integrity

ABU DHABI, UAE and HONG KONG, Oct. 5, 2026 /PRNewswire/ — ICAC Commissioner…

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

The only known investigational therapy for SBMA in Phase 3 development worldwide…